December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

9.950 +0.170 (+1.74%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
Via Investor Brand Network
Topics Government
News headline image
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
From BioMedWire
Via GlobeNewswire
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗
One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗
PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Earnings Preview ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Inc (NASDAQ:FOLD) Q3 2025 Earnings: A Landmark Quarter with Strong Profitability Beat ↗
Amicus Therapeutics (FOLD) beats Q3 2025 earnings estimates with strong revenue growth and a major milestone in profitability, driving positive market momentum. 
Via Chartmill
News headline image
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Via Investor Brand Network
Topics Government
News headline image
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
News headline image
Amicus (FOLD) Q2 Revenue Jumps 22% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Amicus Therapeutics Inc (NASDAQ:FOLD) Beats Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading ↗
Amicus Therapeutics (FOLD) beats Q2 2025 revenue and EPS estimates, driven by strong growth in Galafold and Pompe disease therapies, sparking a 2.77% pre-market rally. 
Via Chartmill
News headline image
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD) 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
From Amicus Therapeutics, Inc.; Dimerix Limited
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.